Presence of late gadolinium enhancement was independently associated with all-cause mortality in end-stage hypertrophic cardiomyopathy (HR 1.52; 95% CI 1.07-2.18; P=0.02).
Cohort (n=691)
Yes
Does the LGE granularity model assessed by CMR predict all-cause mortality in patients with end-stage hypertrophic cardiomyopathy?
In patients with end-stage hypertrophic cardiomyopathy, the LGE granularity model (extent, location, and pattern) assessed by CMR provides strong and independent prognostic value for all-cause mortality.
Effect estimate: HR 1.52 (95% CI 1.07-2.18)
p-value: p=0.02
BACKGROUND: End-stage hypertrophic cardiomyopathy (HCM) is a distinct and advanced form of HCM, defined by a left ventricular ejection fraction <50% and associated with a markedly poor prognosis. Evidence on the prognostic relevance of late gadolinium enhancement (LGE) and its key features in end-stage HCM remains limited. The aim of our study was to evaluate the prognostic value of the LGE granularity model, including its location, extent, and pattern in patients with end-stage HCM. METHODS: All patients referred for cardiovascular magnetic resonance assessment of HCM at 3 French tertiary university hospitals between 2008 and 2024 were retrospectively screened, and all patients with a left ventricular ejection fraction <50% were included. The LGE granularity model was defined as a model combining LGE extent (unique versus multiple involvement), location (septal versus other), and pattern (subepicardial versus midwall). The primary end point was all-cause mortality. RESULTS: Among 2873 patients with HCM, 691 (24%) with end-stage HCM were included (52±7 years, 54% male). After a median follow-up of 9 years (interquartile range, 6–11), 226 patients died (33%). LGE was observed in 259 (37%) patients and was associated with mortality, even after adjustment for classical prognostic factors (hazard ratio, 1.52 95% CI, 1.07–2.18; P =0.02). Each LGE granularity component was independently associated with mortality after adjustment: LGE extent (hazard ratio, 2.85 95% CI, 1.03–7.85; P =0.02), septal location (hazard ratio, 1.73 95% CI, 1.10–2.73; P <0.001), and midwall pattern (hazard ratio, 4.15 95% CI, 1.79–9.61; P <0.001). CONCLUSIONS: In this large multicenter cohort of patients with end-stage HCM, the LGE granularity model integrating LGE extent, location, and pattern provided strong and independent prognostic value.
Hudelo et al. (2026) conducted a cohort in End-stage hypertrophic cardiomyopathy (n=691). Late gadolinium enhancement (LGE) presence and granularity vs. Absence of LGE was evaluated on All-cause mortality (HR 1.52, 95% CI 1.07-2.18, p=0.02). Presence of late gadolinium enhancement was independently associated with all-cause mortality in end-stage hypertrophic cardiomyopathy (HR 1.52; 95% CI 1.07-2.18; P=0.02).